Clinical trial
An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)
NCT03549299 is registered in ClinicalTrials.gov with RHEACELL GmbH & Co. KG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)
- Lead sponsor
- RHEACELL GmbH & Co. KG
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- July 4, 2019
- Completion date
- September 30, 2023
- Enrollment
- 16 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.